Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Surgery. 2020 Jul 5;168(4):737–742. doi: 10.1016/j.surg.2020.04.037

Table 3.

Overall Cohort Outcomes

Variable Overall (n=220) Open (n=69) Minimum (n=151) P value
Hospital stay (days) 2.9 ± 3.4 4.3 ± 4.0 2.0 ± 2.6 <0.001
Operative time (min) 187.2 ± 91.5 223.5 ± 100.4 170.7 ± 82.0 <0.001
ICU stay (days) 0.5 ± 2.0 1.2 ± 2.8 0.2 ± 1.3 <0.001
Post-op complication
  Re-operation 5 (2%) 3 (4%) 2 (1%) 0.16
  Arrhythmia 12 (5%) 7 (10%) 5 (3%) 0.03
  Surgical site infection 3 (1%) 2 (3%) 1 (1%) 0.18
  Neurological deficit 0 0 0 1.00
  Acute kidney injury 1 (0%) 1 (1%) 0 0.13
  30 Day readmission 13 (6%) 5 (8%) 8 (5%) 0.57
Total cost 171,201 ± 14,987 22,847 ± 20,061 14,504 ± 10,845 <0.001
Non Thymoma 179 (81%) 51 (74%) 128 (85%) 0.08
Thymoma 41 (19%) 18 (26%) 23 (15%)
WHO classification
A 4 (10%) 0 4 (17%) 0.18
AB 11 (27%) 6 (33%) 5 (22%) 0.63
B1 10 (24%) 2 (11%) 8 (35%) 0.16
B2 6 (15%) 2 (11%) 4 (17%) 0.90
B3 8 (20%) 6 (33%) 2 (9%) 0.11
C 2 (5%) 2 (11%) 0 0.40
R0 resection 41 (100%) 18 (100%) 23 (100%) 1.00
*

Non Thymoma pathologies included: Thymic cyst, normal thymus, thymic hyperplasia